

Speakers



Dr Katja Aschermann Astator



Dr Rainer Gnibl Local Government of Upper Bavaria



Dr Sabine Hauck Chair of ECA ATMP Interest Group



Kati Kebbel Fraunhofer Institute for Cell Therapy und Immunology



Dr Wolfgang Schumacher ECA Advisory Board



Advanced GMP for ATMPs

Perfect your skills in the ATMP world of GMP and Annex 1



Live Online Training on 29/30 April 2026



Highlights

- Regulatory Overview Part IV
- Impact of Annex 1 in the Aseptic Manufacturing of HCGTP
- Creation of a CCS
- Case Study for a Clinical Phase I/II CAR T Cell Product
- Case Studies of ATIMP Batch Releases

Objective

As part of this GMP course for ATMPs (Advanced Therapy Medicinal Products), you will learn about the existing regulatory requirements for aseptic manufacturing, CCS, data integrity according to the new Annex 1 and much more from various experts from authorities, industry and consulting. In addition to the GMP requirements, you will also learn about the impact and implementation of the new Annex 1.

Background

The new Annex 1 is in effect and must now be implemented. The correct interpretation and implementation in daily business is often difficult and raises many questions. Compliance with the GMP regulations is essential for the continuous, traceable and high-quality manufacture, testing and control of pharmaceutical products.

Advanced Therapy Medicinal Products (ATMPs) are a group of innovative and sophisticated medical treatments that use advanced technologies to modify or use living cells, tissues or genes for therapeutic purposes. These therapies focus on targeting the underlying causes of disease at the cellular and genetic level, with the aim of treating, preventing or diagnosing diseases. ATMPs include gene therapies, cell therapies and tissue engineered products and represent a significant step in medical treatments.

New ATMPs with innovative properties are constantly being developed. It does not matter whether it is a personalized product, production or even transport. The ultimate goal always remains a safe and effective product that provides the patient with healing or relief without harming them. To ensure this, employees must comply with the current regulations. This course offers deeper insights into the regulations and advice on implementing the new and existing requirements of ATMPs.

Target Audience

This training is aimed at employees from quality assurance, quality control and production who have daily contact with ATMPs and have to work according to the existing GMP requirements. Experienced staff will have the opportunity to extend and deepen their existing knowledge in core aspects of GMP and Annex 1 areas.

Moderator

Clemens Mundo, Concept Heidelberg

Programme

EU-GMP Guideline Part IV: Overview Dr Rainer Gnibl

- Positioning within EudraLex Vol. 4
- Definition of ATMPs
- Document structure & technical content
- Key messages

Quality Risk Management for ATMPs Dr Rainer Gnibl

- What does QRM mean?
- ICH Q9 Quality Risk Management (Overview)
- Bounderies & limitations
- Examples from guideline

Specific Aspects for Viral and non-viral Vectors Dr Sabine Hauck

- Points to consider when handling GMOs under GMP
- GMPs and Pharm. Eur. monograph on gene therapy medicinal products
- Viral clearance of viral products

Aseptic Manufacturing of Cell-based ATMPs (HCGTP) Dr Katja Aschermann

- Challenges
- Impact of new Annex 1
- Cross Contamination Control Strategy

Environmental Monitoring Dr Rainer Gnibl

- Segregation between Classification, Qualification & Monitoring
- Clean room lifecycle
- Monitoring elements
- Personell & clean room monitoring

Data Integrity of Automated, Decentralised Cell Therapy Production

Dr Wolfgang Schumacher

- DI concept in research-oriented smaller companies
- Computer-assisted manufacturing of therapeutics
- DI issues in testing, release and logistics
- Impact of the revised EU GMP Chapter 4, Annex 11 and new Annex 22
- DI questions in the context of inspections

Contamination Control Strategy Dr Katja Aschermann

- Definition
- Creation of a CCS
- Selected items

Qualification and Validation – A Versatile and Efficient Quality Tool in the ATMP Manufacturing Kati Kebbel

- Clarification of types of qualification and validation applied in ATMP manufacturing
 - supplier qualification
 - device qualification
 - software validation
- (Aseptic) process qualification / validation
 - method validation
 - operator qualification
- Regulatory basis
- How are these types used in the ATMP manufacturing described in a case study for a clinical phase I/II ATMP

ATMPs – A Challenge for Quality Control Dr Katja Aschermann & Dr Sabine Hauck

- From product to control strategy via CQAs
- Measurement of quality attributes
- Specifications
- Stability
- Validation

Regulatory Landscape – Opportunities and Challenges Dr Sabine Hauck

- Overview for ATMPs
- Specific requirements for ATMPs opportunities and challenges
- Examples on points to consider in CMC

If the Guidelines Become a Challenge Kati Kebbel

- Media Growth Promotion Test according to EP 2.6.1 vs.
 2.6.27 and impact to sterility method validation
- APS challenges
- Change of standard APS strategy a future vision?

Batch Release – Responsibilities and Challenges of a QP Based on Case Studies from an Academic CDMO Kati Kebbel

- Regulatory landscape batch release process;
 2-step-procedure for certification of ATIMPs and sponsor release
- Case Study 1: product certification of an early clinical stage ATIMP - roles of the QP in an academic project setting
- Case Study 2: product certification of an early clinical stage IMP with different manufacturing sites – roles of the QP(s) and division of responsibilities
- Case Study 3: product certification roles of the QP(s) in a pharma project setting

Speakers



Dr Katja Aschermann Astator, Consultant

Dr Katja Aschermann is an accomplished leader in the biopharmaceutical industry with over 20 years of

experience in various senior positions. Her extensive experience spans from transforming academic spin-offs into GMP companies to submitting regulatory dossiers to the EMA. She is a member of the ECA ATMP-Interest Group Board and has participated in the development of the "National Strategy for Gene and Cell-Based Therapies". In Nov 2024 she started working as a freelance consultant.



Dr Rainer Gnibl Local Government of Upper Bavaria GMP Inspector for EMA and local Government

Dr Rainer Gnibl is pharmacist and GMP Inspector for the District Government of Upper Bavaria and the EMA and performs GMP-inspections worldwide. Before that, he was working for the Bavarian Ministry of Environment and Health.



Dr Sabine Hauck dequra pharma consult hauck

Sabine Hauck has 20+ years of experience in the biotech industry, in which she held various positions in pharma-

ceutical development, quality assurance, regulatory affairs and corporate development. After gaining experience in several biotech companies she is now providing freelance consulting and trainings for biotech and biopharma companies. Sabine is also active as the chair of the ECA ATMP interest group.



Kati Kebbel Fraunhofer Institute for Cell Therapy und Immunology, Head of Department GMP Cell and Gene Therapy, Qualified Person

Kati Kebbel has been working in the field of ATMP Manufacturing, Quality Control and Quality Assurance for more than 17 years. She is heading the department GMP Cell and Gene Therapy and in addition, she is Qualified Person. In her current position she supported several process transfers from US to Germany, established new manufacturing processes / methods, drove process and method qualifications and supports regulatory submissions.



Dr Wolfgang Schumacher Principal Consultant

After entering Asta Medica, Dr Schumacher headed different positions. From 2001 to 2016 he was Head of the

department of Quality Computer Systems at F. Hoffmann-La Roche, Basle. He is a member of the ECA Advisory Board. Currently he works as a consultant.

Live Online Training on 29/30 April 2026

Advanced GMP for ATMPs

fthe bill-to-address deviates from the specificaions on the right, please fill out here:

Purchase Order Number, if applicable Company Important: Please indicate your company's VAT ID Number ZIP Code itle, first name, surname E-Mail (Please fill in) Department Phone / Fax City Fax +49 (0) 62 21/84 44 34 CONCEPT HEIDELBERG D-69007 Heidelberg P.O. Box 101764 GERMANY

for which I hereby declare to agree that my personal data is stored and processed. Concept Beidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, note that I can ask for the modification, correction or deletion of my data at any

If you cannot take part, you have to inform us in will then be calculated according to the point of cancellation fee

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receip to fip ayment will not be confirmed)) (As of january 2012). German law shall apply. Court of jurisdiction is Heidelberg. time at which we receive your message.

nalties or other costs incurred due to a cancellation. Terms of payment: Payable without deductions within 10 days after receipt of Important: This is a binding registration and above fees are due in case of can-

invoice.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of

fees paid. CONCEPT HEIDELBERGwill not be responsible for discount airfare pe-

Date of the Live Online Training

Wednesday, 29 April 2026, 09.00 h - 16.30 h Thursday, 30 April 2026, 09.00 h - 16.00 h All times mentioned are CEST

Fees (per delegate, plus VAT)

ECA Members € 1,890 APIC Members € 1,990 Non-ECA Members € 2,090 EU GMP Inspectorates € 1,045 Academic Scientists/ Students € 1,045 The conference fee is payable in advance after receipt of

Technical Requirements

We use Webex for our live online training courses and webinars. At https://www.gmp-compliance.org/training/onlinetraining-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.

Registration

Via the attached reservation form, by e-mail or by fax - or search and register directly at www.gmp-compliance.org under the number 22522. To avoid incorrect information, please give us the exact address and full name of the par-

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

You cannot attend the Live Online Event?

We also offer many of the training courses and conferences as recordings. This means that you can watch the videos of the event "on demand" – whenever it suits you – on our web server. It is quite uncomplicated and doesn't require any software – you simply watch the video on your browser. You can find all recorded events at www.gmp-compliance.org/ recordings.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event. CONCEPT HEIDELBERG P.O.Box 10 17 64 | 69007 Heidelberg, Germany Phone: +49(0)62 21/84 44 0 | Fax: +49(0)62 21/84 44 34 info@concept-heidelberg.de | www.concept-heidelberg.de

For questions regarding content please contact: Mr Clemens Mundo (Operations Director) at +49(0)62 21/84 44 42 or at mundo@concept-heidelberg.de

For questions regarding organisation please contact: Ms Sonja Nemec (Organisation Manager) at +49(0)62 21/84 44 24 or at nemec@concept-heidelberg.de

WA/27082025

Cancellation within 2 weeks prior to the conference 100 %